1.
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
by Matthews, David R
Diabetologia, 2019-06, Vol.62 (6), p.926-938
2.
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
by Oshima, Megumi
Diabetologia, 2019-07-13, Vol.62 (11), p.1988-1997
3.
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
by Zhou, Zien
Diabetologia, 2019-10, Vol.62 (10), p.1854-1867
